-+ 0.00%
-+ 0.00%
-+ 0.00%

Rigel Pharmaceuticals Launches New Phase 2 Trial of Olutasidenib in IDH1-Mutated Myeloid Malignancies

Reuters·11/17/2025 13:05:55

Please log in to view news